Artemis Therapeutics, Inc. (OTCMKTS:INKSD) Files An 8-K Regulation FD Disclosure

Artemis Therapeutics, Inc. (OTCMKTS:INKSD) Files An 8-K Regulation FD Disclosure

Story continues below

Item 7.01.

Regulation FD Disclosure.
Attached as Exhibit 99.1 to this Current Report on Form 8-K is an
investor presentation (the Presentation), which Artemis
Therapeutics, Inc. (the Company) may use in presentations to
investors from time to time. The Presentation will be accessible
online through the Investor Relations section of the Companys
website at The
information on the Companys website is not part of this Form 8-K.
The Company undertakes no obligation to update, supplement or
amend the materials attached hereto as Exhibit 99.1.
The information provided to this Item 7.01, including Exhibit
99.1 in Item 9.01, is furnished and shall not be deemed to be
filed with the Securities and Exchange Commission or incorporated
by reference in any filing under the Securities Exchange Act of
1934, as amended, or the Securities Act of 1933, as amended,
except as shall be expressly set forth by specific reference in
any such filings.
Item 9.01.
Financial Statements and Exhibits
(d) Exhibits
Investor Presentation

About Artemis Therapeutics, Inc. (OTCMKTS:INKSD)

Artemis Therapeutics, Inc., formerly New York Global Innovations Inc., seeks to offer alternatives to allergy medications. The Company provides various dietary and lifestyle guidelines, and also offers Lucidia and approximately six Chinese herb support formulas for purchase or prescription filling. The Company offers Artemis Allergy Relief Program, which is an educational resource center for health care practitioners, patients, and anyone suffering from seasonal, environmental or pet allergies. The program is a natural approach to allergy treatment or can be used alongside various therapies. The program provides various tools and natural medicinals to cultivate health and mitigate allergy symptoms. Artemis Allergy Treatment Program is intended for people suffering from seasonal allergies or yearlong allergies to pollens, animals, mold, dust, grasses, trees and hay fever.

Artemis Therapeutics, Inc. (OTCMKTS:INKSD) Recent Trading Information

Artemis Therapeutics, Inc. (OTCMKTS:INKSD) closed its last trading session 00.000 at 0.700 with shares trading hands.

An ad to help with our costs